ClinicalTrials.gg
RecruitingNCT04629833IDUNNUpdated Aug 13, 2025

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

A Phase 3 interventional study of MC0518 and BAT in Steroid-refractory Acute Graft-versus-host Disease, sponsored by medac GmbH. Recruiting at 42 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by medac GmbH · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 53 studies in Graft vs Host Disease with a site in Germany — 3 open to participants now, 9 under way, 4 of them phase 3. Graft vs Host Disease · Germany.

Planned enrollment
11th of 44
210 · median 69
Started
2021
with 3 others
Phase 3
17 of 53
1 open now
Registered
43rd of 53
by date
Lead sponsor
2 of 53
medac GmbH

Among the 53 studies in Graft vs Host Disease with a site in Germany, this one is the 11th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2021, is one of 17 in phase 3, and was the 43rd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 148 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

3 of the 53 studies in Graft vs Host Disease with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graft vs Host Disease with a site in Germany, or all of them as a file.
02

Study summary

The primary purpose of this trial is to demonstrate the superiority of MC0518 compared to the first used best available therapy (BAT) with respect to overall response rate (ORR) at Day 28 and/or overall survival (OS) until Visit Month 24 in adult and adolescent subjects with steroid-refractory acute graft-versus-host disease (SR-aGvHD).

03

Conditions studied

  • Steroid-refractory Acute Graft-versus-host Disease

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant had a previous HSCT as indicated for non-malignant (including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies, and bone marrow failure syndromes) or haematological malignant disease, irrespective of human leukocyte antigen match
  • Participant has been clinically diagnosed with Grade II to IV aGvHD at the Screening Visit
  • Participant has experienced failure of previous aGvHD treatment (ie, SR-aGvHD), defined as: a) aGvHD progression within 3 to 5 days of therapy onset with >= 2 mg/kg/day of prednisone equivalent or b) failure to improve within 5 to 7 days of treatment initiation with >= 2 mg/kg/day of prednisone equivalent or c) incomplete response after > 28 days of treatment including at least 5 days with >= 2 mg/kg/day of prednisone equivalent
  • Participant has an estimated > 28 days at the Screening Visit
  • Male or female participant who is >= 12 years of age at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  • Participant has overt relapse or progression or persistence of the underlying disease at the Screening Visit
  • Participant has received the last for a solid tumour disease
  • Participant has GvHD overlap syndrome at the Screening Visit
  • Participant has received systemic treatment for aGvHD other than and a prophylaxis with other than calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, anti-thymocyte globulin (ATG), mycophenolate mofetil (MMF), methotrexate (MTX), and / or cyclophosphamide before the Screening Visit
  • Participant has a known pregnancy (as confirmed by a positive pregnancy test at the Screening Visit) and or is breastfeeding at the Screening Visit
  • Participant has received treatment with any other agent within 30 days or 5 half-lives (whichever is longer) before the Screening Visit (compliance to be confirmed for the period between the Screening Visit and the Baseline Visit at the Baseline Visit).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    MC0518

    Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.

    Biological: MC0518

  • Active comparator
    Best Available Therapy (BAT)

    Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX).

    Biological: BAT

Interventions

  • BiologicalMC0518

    MC0518 will be intravenously infused immediately after thawing.

  • BiologicalBAT

    BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.

06

What researchers measure

Primary outcomes

  1. Overall Response (OR)

    OR is defined as complete response (CR) or partial response (PR) at Day 28 relative to aGvHD status at baseline. CR is defined as resolution of aGvHD in all involved organs. PR is defined as improvement in 1 stage in 1 or more organs involved with aGvHD symptoms without progression in others. Number of participants with OR will be reported.

    Time frame: Day 28

  2. Overall Survival

    Overall survival is defined as the time from randomization to the date of death due to any cause.

    Time frame: Up to Month 24

Secondary outcomes

  1. Freedom from Treatment Failure (FFTF)

    FFTF is defined as death, relapse or progression of the underlying disease, or addition or change to any further systemic immunosuppressive aGvHD therapy. Number of participants with FFTF will be reported.

    Time frame: Up to 6 months

  2. Acute Graft-versus-host Disease (aGvHD) Response

    Number of participants with aGvHD response will be reported. aGvHD response will be categorized as OR (CR + PR), CR, PR, and NR. NR is defined as the absence of CR or PR.

    Time frame: Days 28, 60, 100 and 180

  3. Change from Baseline in aGvHD Grades

    aGvHD grades: Grade 0- no organ involvement (ie, Stage 0 skin, Stage 0 liver, and Stage 0 GI); Grade I-Stage 1 - 2 skin without liver/GI involvement; Grade II- Stage 3 skin and / or Stage 1 liver and / or Stage 1 GI; Grade III- Stage 2 - 3 liver and / or Stage 2 - 3 GI; Grade IV- Stage 4 skin and / or Stage 4 liver and/or Stage 4 GI.

    Time frame: Baseline and Days 8, 15, 22, 28, 60, 100 and 180

  4. Time to Response

    Time to response is defined as the time from the date of the first treatment administration to the date of response.

    Time frame: Up to Month 24

  5. Duration of Response

    Duration is calculated from time from the first OR (CR or PR) until the time point of no aGvHD response in comparison to baseline.

    Time frame: Up to Month 24

  6. Best Overall Response (OR)

    Best OR is defined as the achievement of an OR at any time point up to and including Day 28. Number of participants with best OR will be reported.

    Time frame: Up to Day 28

  7. Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight

    The cumulative dose of steroids given for SR-aGvHD per kg of body weight from baseline until Day 60 and until Visit Month 24 will be analyzed.

    Time frame: Up to Day 60 and Month 24

  8. Number of Participants with Chronic Graft-versus-host Disease (cGvHD)

    Number of participants with cGvHD will be reported.

    Time frame: Day 60 to Month 24

  9. Time to Chronic Graft-versus-host Disease (cGvHD)

    Time to cGvHD is defined as the time between the last day of haematopoietic stem cell transplantation (HSCT) to the first episode of cGvHD.

    Time frame: Day 60 to Month 24

  10. Number of Participants with Graft Failure (GF)

    Number of participants with GF will be reported.

    Time frame: Up to Month 24

  11. Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease

    Number of participants with relapse or progression in participants with underlying malignant disease will be reported.

    Time frame: Up to Month 24

  12. Time to Relapse or Progression in Participants with Underlying Malignant Disease

    Time to relapse or progression in participants with underlying malignant disease will be reported.

    Time frame: Up to Month 24

  13. Event-free survival (EFS)

    EFS is defined as the time from the date of randomization to the date of the event. An event is defined as GF, relapse or progression of the underlying disease, or death due to any cause.

    Time frame: Up to Month 24

  14. Non-relapse Mortality (NRM)

    NRM is defined as the time from the date of randomisation to the date of the event. An event is defined as death without previous relapse or progression of the underlying disease.

    Time frame: Up to Month 24

  15. Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)

    Time frame: Until Day 60 or until 30 days after last administration of trial treatment, whichever is later (Up to Month 24)

  16. Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity

    Severity will be graded based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 4- Death related to the AE.

    Time frame: Until Day 60 or until 30 days after last administration of trial treatment, whichever is later (Up to Month 24)

  17. Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)

    The Karnofsky performance score (KPS), which is reported on an ordinal scale from 0 to 100, provides a rough measure of the participant's well-being, including their ability to conduct activities of daily living and functional capacity. Higher score indicates normal, no complaints and no evidence of disease.

    Time frame: Baseline, Days 8, 15, 22, 28, 60 and 100

  18. Change from Baseline in Performance score based on Lansky Scale

    A Lansky score (recipient age greater than or equal to \[\>=\] 1 years and less than \[\<\] 16 years) will be recorded pre-treatment and measured serially at regular intervals after treatment. The score is a standard performance score that measures overall function of the child with a scale range from 0 to 100. Higher score indicates full activeness.

    Time frame: Baseline, Days 8, 15, 22, 28, 60 and 100

  19. Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "TODAY". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health).

    Time frame: Baseline, Days 28, 60, 100 and 180

  20. Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).

    Time frame: Baseline, Days 28, 60, 100 and 180

  21. Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score

    The FACT-BMT questionnaire was designed to measure the quality of life in subjects undergoing bone marrow (BM) transplantation. It consists of the following categories of assessment: physical well-being, social / family well-being, emotional well-being, functional well-being, and additional miscellaneous concerns that the subject may have concerning their healthcare, persons involved in their life, and other emotions and incapabilities. Score ranges from 0-164, with higher score indicating better quality of life.

    Time frame: Baseline, Days 28, 60, 100 and 180

07

Study locations

35 of 42 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Aug 2027, 72 months after the start.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's planned 72 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2020
First posted
Nov 16, 2020
StartActual
Aug 16, 2021
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2030
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04629833
Lead sponsor
medac GmbH
Responsible party
Sponsor
First posted
Nov 16, 2020
Start date
Aug 16, 2021
Primary completion
Aug 2027 (estimated)
Completion
Aug 2030 (estimated)
Last update
Aug 13, 2025

Study contacts

Clinical Trial Information
Contact
ClinicalTrialInformation@medac.de
+49 40103 8006-0
Ann-Kristin Möller
study director · medac GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion